These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29518420)

  • 1. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
    Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
    Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
    Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 5. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
    Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
    Cho YT; Fu KT; Yang CW; Chu CY
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic autoimmune urticaria with omalizumab.
    Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.
    Palacios T; Stillman L; Borish L; Lawrence M
    J Allergy Clin Immunol Pract; 2016; 4(3):529-30. PubMed ID: 26725153
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
    Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H
    J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria.
    Sheikh J
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):88; author reply 88-9. PubMed ID: 18254490
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
    Asero R
    Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
    Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
    [No Abstract]   [Full Text] [Related]  

  • 16. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?].
    Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A
    Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
    Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
    Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
    [No Abstract]   [Full Text] [Related]  

  • 19. The basophil proteome in chronic spontaneous urticaria distinguishes responders to omalizumab from non-responders.
    Stitt JM; Dzieciatkowska M; Edwards MG; Hansen K; Hedlund G; Dreskin SC
    Clin Exp Allergy; 2018 Jul; 48(7):898-901. PubMed ID: 29671921
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
    Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
    J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.